Anthony Linton
YOU?
Author Swipe
View article: Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial
Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial Open
This pilot demonstrates that a phase III clinical trial of extended continuous subcutaneous infusion of lidocaine for neuropathic cancer pain is feasible and provides important insights into modifications required to improve recruitment. S…
View article: A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma Open
Background Finding effective and curative treatment for mesothelioma remains challenging. While the introduction of immunotherapy combinations using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have offered hope for some patients, a …
View article: Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer Open
Older Australian patients receiving consolidation durvalumab following CRT experienced comparable outcomes to their younger peers. Comorbidity burden may be more important determinants of treatment tolerance than chronological age.
View article: High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma
High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma Open
Aims Mesothelin (MSLN) is a cancer‐associated antigen that is overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It is also a target for novel personalised therapies, including antibodies, antibody–drug conj…
View article: Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study Open
Introduction Many patients experience unrelieved neuropathic cancer-related pain. Most current analgesic therapies have psychoactive side effects, lack efficacy data for this indication and have potential medication-related harms. The loca…
View article: 3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies
3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies Open
Traditional studies using cancer cell lines are often performed on a two-dimensional (2D) cell culture model with a low success rate of translating to Phase I or Phase II clinical studies. In comparison, with the advent of developments thr…
View article: Issue Information
Issue Information Open
Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis Giuseppe Colloca 240 Resection arthrodesis and osteoarticular allografts re…
View article: GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel <i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol) Open
Objective: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 ( mGSTP1) in men with metastatic castration-resistant prostate cancer (CRPC). Patients a…
View article: RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL
RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL Open
BACKGROUND Survival outcomes for patients with newly diagnosed glioblastoma have not changed significantly since the introduction of concurrent temozolomide with post-surgical radiation followed by adjuvant temozolomide. METHODS Multi-Arm …
View article: The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) Open
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in th…
View article: The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia‐Pacific Region
The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia‐Pacific Region Open
Malignant pleural mesothelioma (MPM) is an incurable malignancy associated with high symptom burden and poor prognosis. The relationship between asbestos exposure and MPM incidence is well‐established. The incidence rate of MPM in Australi…
View article: CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation
CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation Open
Our study confirms that MTAP is often co-deleted with CDKN2A in MPM. Our in-house designed ddPCR assays for MTAP and CDKN2A are useful in differentiating MPM from RMH, and is highly concordant with FISH that is currently used in diagnosing…
View article: Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer Open
PURPOSE: To identify the approximately 12% with inherited cancer predisposition, all men with metastatic prostate cancer (mPC) should be offered germline genetic testing. This guides treatment choices and impacts cancer prevention in the f…
View article: The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer Open
Yuen Yee Cheng, 1, 2 Emma M Rath, 3 Anthony Linton, 1, 2, 4 Man Lee Yuen, 1 Ken Takahashi, 1 Kenneth Lee 1, 2, 4 1Asbestos Disease Research Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; 2Sydne…
View article: <p>The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer</p>
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer Open
Asbestos is a naturally occurring mineral consisting of extremely fine fibres that can become trapped in the lungs after inhalation. Occupational and environmental exposures to asbestos are linked to development of lung cancer and malignan…
View article: IMMU-50. THE IMMUNE LANDSCAPE OF BLOOD DENDRITIC CELLS IN GLIOBLASTOMA MULTIFORME: IMPLICATIONS FOR DC VACCINATION COMBINED WITH CHECKPOINT INHIBITION
IMMU-50. THE IMMUNE LANDSCAPE OF BLOOD DENDRITIC CELLS IN GLIOBLASTOMA MULTIFORME: IMPLICATIONS FOR DC VACCINATION COMBINED WITH CHECKPOINT INHIBITION Open
Therapeutic dendritic cell vaccination for GBM using primary blood dendritic cells (BDC) has the potential to improve response rates compared with more commonly used monocyte-derived dendritic cells due to their superior antigen-presentati…
View article: Erratum: An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
Erratum: An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma Open
Correction to: British Journal of Cancer (2014) 110, 510–519. doi:10.1038/bjc.2013.731; published online 10 December 2013 The name of the fourth author was omitted. The author is Lyn Schedlich, and all the author names and affiliations are…
View article: miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma Open
Malignant pleural mesothelioma (MPM) is an asbestos-induced cancer with poor prognosis that displays characteristic alterations in microRNA expression. Recently it was reported that the expression of a subset of microRNAs can distinguish b…